Aktis Oncology (NASDAQ:AKTS – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a report issued on Friday, Benzinga reports. They presently have a $35.00 price objective on the technology company’s stock. Wedbush’s price target would indicate a potential upside of 90.03% from the stock’s current price.
Other analysts have also recently issued reports about the stock. Raymond James Financial initiated coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective for the company. Oppenheimer initiated coverage on shares of Aktis Oncology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price objective for the company. Wall Street Zen cut shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Aktis Oncology in a research report on Friday, September 18th. Finally, BMO Capital Markets assumed coverage on shares of Aktis Oncology in a research report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.63.
Check Out Our Latest Stock Report on Aktis Oncology
Aktis Oncology Price Performance
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last released its earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.70 million. As a group, sell-side analysts anticipate that Aktis Oncology will post -1.85 EPS for the current year.
Insider Buying and Selling
In other Aktis Oncology news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the transaction, the director owned 3,506 shares in the company, valued at $86,107.36. The trade was a 58.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 3.30% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Aktis Oncology
A number of institutional investors have recently modified their holdings of AKTS. State of Wyoming acquired a new stake in shares of Aktis Oncology in the 2nd quarter valued at about $32,000. AXQ Capital LP acquired a new stake in shares of Aktis Oncology in the 2nd quarter valued at about $226,000. Susquehanna International Group LLP bought a new stake in shares of Aktis Oncology during the 2nd quarter valued at about $278,000. Deutsche Bank AG grew its position in shares of Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after buying an additional 6,942 shares during the last quarter. Finally, Readystate Asset Management LP bought a new stake in shares of Aktis Oncology during the 2nd quarter valued at about $967,000. Institutional investors and hedge funds own 28.84% of the company’s stock.
Aktis Oncology Company Profile
Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.
The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.
Featured Stories
- Five stocks we like better than Aktis Oncology
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
